Strumento inattivo

Azioni Raptor Pharmaceutical Corp

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Depomed : Le laboratoire Depomed résigné à se vendre-sources	16/09/16
Exclusive: Drugmaker Depomed prepares to explore a sale - sources	15/09/16
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information	15/09/16
Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders	14/09/16
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information	12/09/16

Dirigenti	Titolo	Età	Da
Paul Hoelscher DFI	Director of Finance/CFO	59	25/10/16
Kim Lee IRC	Investor Relations Contact	-	23/10/14
Françoise de Craecker PRN	Corporate Officer/Principal	62	-

Amministratori	Titolo	Età	Da
Gregg Lapointe CHM	Chairman	65	01/01/15
Timothy Walbert BRD	Director/Board Member	57	11/04/11
Paul Hoelscher DFI	Director of Finance/CFO	59	25/10/16

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd